ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2026
Romosozumab mitigates progression from radiological to symptomatic adjacent-level fractures compared to teriparatide.
Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Single-component imaging and ultrasound-based tools for the assessment of fracture risk.Nature reviews. Rheumatology · 2026Review
- Comment on: The association of bone density and hip fracture risk among Asian women.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- T-score, stature, and fracture risk interpretation in Asian women.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Romosozumab and teriparatide were compared for preventing symptomatic subsequent vertebral compression fractures (SVCF) after cement augmentation. Across multicenter and hospital-based cohorts, Romosozumab significantly reduced the 2-year incidence and adjusted risk of symptomatic SVCF, particularly adjacent-level fracture, mainly by lowering conversion rate from radiological to symptomatic fractures requiring surgical intervention.
introductionSubsequent vertebral compression fracture (SVCF) was a frequent and severe complication after vertebral cement augmentation, particularly in elderly patients with osteoporosis. This study aimed to compare the effectiveness of romosozumab (RM) and teriparatide (TP) in preventing symptomatic SVCF requiring subsequent operation.
methodsThis study comprised two cohorts. The first, derived from the Taipei Medical University Clinical Research Database (TMUCRD), included 813 patients who received RM or TP within three months before or after cement augmentation for osteoporotic vertebral compression fracture. Symptomatic SVCF, defined as requiring subsequent vertebral cement augmentation, was compared over a two-year follow-up. The second, a hospital-based cohort of 147 patients from Taipei Medical University Hospital (TMUH), additionally assessed radiographic outcomes.
resultsIn the TMUCRD cohort, the RM group showed a significantly lower 2-year incidence of symptomatic SVCF than the TP group (3.61% vs 11.44%, p = 0.003). In the TMUH cohort, symptomatic SVCF occurred particularly at adjacent levels. Although the incidence of radiological adjacent-level SVCF and postoperative analgesic consumption were comparable between groups, RM-treated patients demonstrated lower operation conversion rate (21.1% vs. 59.1%, p = 0.03), indicating that fewer radiological adjacent-level SVCF progressed to symptomatic requiring surgical intervention.
conclusionRM was associated with a lower incidence of symptomatic adjacent-level SVCF compared to TP. This difference was not attributed to a lower incidence of radiological SVCF, but rather to a reduced conversion rate from radiological to symptomatic fractures requiring surgical intervention.
Indexed as
Identifiers
41400654What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.